The CEBPA Knockout AGS Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of human AGS gastric adenocarcinoma cells bearing targeted disruption of the CEBPA gene. As a polyclonal knockout product, this pool encompasses a variety of edited alleles and is not derived from a single-cell clone, thus recapitulating the genetic mosaic more typical of bulk-edited cultures. This format is particularly useful for functional studies where clonal variability may confound results, enabling robust assessment of CEBPA loss of function in gastric epithelial biology.
The AGS cell line, established from a human gastric adenocarcinoma, retains key features of gastric epithelial cells and is a widely accepted model for gastric cancer studies. AGS cells are frequently employed to investigate proliferation, apoptosis, drug sensitivity, and oncogenic signaling pathways. Their robust growth and manipulability make them a preferred host for CRISPR-based genome editing. This line’s well-characterized biology allows reliable interpretation of phenotypic changes following gene disruption, such as those observed in CEBPA knockout populations.
CEBPA encodes a basic leucine zipper transcription factor that acts as a master regulator of cell differentiation and proliferation. In gastric epithelial cells, it functions as a tumor suppressor by directly transactivating the cyclin-dependent kinase inhibitor CDKN1A (p21), thereby enforcing cell cycle arrest, and by repressing the oncogene MYC. Signal transduction pathways including MAPK, PI3K/AKT/mTOR, and metabolic sensors such as PPAR?? and SREBP-1 modulate CEBPA activity, while its expression is epigenetically silenced in some contexts by promoter CpG island methylation via GLI1. CEBPA physically interacts with the transcriptional co-activators EP300 and CREBBP, heterodimerizes with CEBPB and CEBPD to diversify target recognition, and associates with RB1, CDK2, and NFKB1, integrating cell cycle and inflammatory cues. Downstream, CEBPA promotes expression of PPARG, GCSFR, and GLUT4, while negatively regulating the anti-apoptotic protein BCL2; knockout of CEBPA thus ablates a multifaceted network controlling growth, differentiation, and metabolism.
In the AGS gastric cancer context, CEBPA knockout eliminates its growth-suppressive constraints, leading to accelerated proliferation and impaired cell cycle control. The provided mechanistic summary indicates that CEBPA disruption reduces p21 and increases MYC activity, consistent with a switch to a more aggressive phenotype. Because CEBPA is frequently inactivated in gastric tumors via promoter methylation or genetic alterations, this polyclonal model recapitulates a clinically relevant state of CEBPA deficiency. It offers a valuable system to dissect tumor-suppressive mechanisms in gastric epithelium and to test pharmacological strategies aimed at restoring CEBPA function or counteracting downstream oncogenic signals.
This knockout model is suited for gastric cancer research, tumor suppressor gene studies, and investigation of drug resistance mechanisms. Compatible assays include Western blotting and RT-qPCR for CEBPA, p21, and MYC; proliferation assays (MTT, BrdU); colony formation; migration/invasion assays; flow cytometry for cell cycle; RNA-seq transcriptomics; and ChIP-seq in wild-type cells. These tools enable comprehensive functional dissection of CEBPA-dependent pathways in a gastric cancer setting. For ordering or technical support, please contact Ascent Research.
